RNA Editing Pionee | Korro Bio leads in RNA editing therapies, with KRRO-110 for AATD showing promising preclinical results and potential best-in-class profile |
Market Potential | AATD market estimated to reach $20 billion by 2035, with no approved disease-modifying therapies, presenting a significant opportunity for Korro Bio |
Competitive Edge | Explore Korro's strategic advantage in reversible RNA editing, attracting interest from major pharma companies and offering a potentially safer approach |
Financial Outlook | Analysts project improving financials with EPS moving from -$51.52 to -$8.56. Price targets range from $105 to $120, reflecting optimism for future growth |
Metrics to compare | KRRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipKRROPeersSector | |
---|---|---|---|---|
P/E Ratio | −3.1x | −0.8x | −0.7x | |
PEG Ratio | −0.44 | −0.02 | 0.00 | |
Price/Book | 1.5x | 1.1x | 2.6x | |
Price / LTM Sales | - | 45.3x | 3.1x | |
Upside (Analyst Target) | 382.6% | 681.0% | 49.4% | |
Fair Value Upside | Unlock | 16.7% | 8.9% | Unlock |